Kornimate/medical-research-clean huggingface dataset:
cross-sectional study on a given day within the paris saint-joseph hospital group

Conditions: Sleep Apnea

Summary: sleep apnea syndrome has an estimated incidence of 2 to 4% in the adult population and more so in men and with aging. it is an independent risk factor for mortality. cardiovascular pathologies, diabetes, and stroke are known comorbidities with a high rate of association. there is no recommendation to screen these patients although the interest is assumed and sleep apnea syndrome is largely underdiagnosed. interrogation and clinical examination guide but they are neither sensitive nor specific. the use of scores improves screening. in the general population, the berlin score has a high false negative rate. the stop-bang score is sensitive but with a poor positive predictive value. combined, these scores can be used to detect sleep apnea syndrome. the interest of a management was especially shown for the very symptomatic syndromes because it is a pledge of observance of the treatment, itself necessary for the effectiveness in the prevention of the cardiovascular complications.


Eligibility criteria:
inclusion criteria: * patient whose age is\> 18 years * any patient hospitalized on the day of the survey in any of the services of the cardio-neurovascular division of the paris saint-joseph hospital group, whatever the history of comorbidities, the reason for hospitalization * francophone patient exclusion criteria: * patient under tutorship or curatorship * patient deprived of liberty * patient at the end of life * patient opposing his participation in the research protocol
implementation of climb up program for children with attention deficit hyperactivity disorder (adhd) and dyslexia in a school in india

Conditions: Attention Deficit Hyperactivity Disorder; Dyslexia

Summary: a multimodal intervention was rolled out at a large public school in najibabad, uttar pradesh (up). the program identified elementary school children with adhd and dyslexia using standard screening of all children who had performance impairment in at least one domain of the vanderbilt questionnaire. the program consisted of play therapy, physical exercise, yoga and meditation. the program was established by high school volunteers from the us and uk over 6 weeks. once implemented during the morning of school, high school volunteers from the school were trained to continue the program. vanderbilt questionnaires were completed at intervals to allow follow up.


Eligibility criteria:
inclusion criteria: * all children between 6 and 11 years attending mdkv public school in najibabad, up who had assessment performed for adhd or dyslexia exclusion criteria: * children who were not enrolled by the parents

Keywords: performance impairment yoga meditation peer mediated
drug-drug interaction study between edp-938, itraconazole, rifampin, and quinidine in healthy subjects

Conditions: RSV Infection

Summary: a non-randomized, open-label, three-part, drug-drug interaction study to evaluate the effects of itraconazole, rifampin, and quinidine on the pharmacokinetics and safety of edp-938 in healthy subjects


Eligibility criteria:
inclusion criteria: * an informed consent document signed and dated by the subject. * healthy male and female subjects of any ethnic origin between the ages of 18 and 55 years, inclusive. * screening body mass index (bmi) of 18 to 30 kg/m2 with a minimum body weight of 50 kg * female subjects of childbearing potential must agree to use two effective methods of contraception from the date of screening until 90 days after the last dose of edp 938. exclusion criteria: * clinically relevant evidence or history of illness or disease. * for part 3 subjects, the following cardiovascular abnormalities: * qrs duration \>110 ms * incomplete right bundle branch block or any complete bundle branch block * heart rate \ 90 beats per minute (per vital sign capture while rested) * history of unexplained syncope, structural heart disease, or clinically significant arrhythmias * personal or family history of long qt syndrome (genetically proven or suggested by sudden death of a close relative due to cardiac causes at a young age) or brugada syndrome * pr interval \>220 ms or any 2nd or 3rd degree av block * ventricular pre-excitation * pregnant or nursing females. * history of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection. * a positive urine drug screen at screening or day -1. * current tobacco smokers or use of tobacco within 3 months prior to screening. * any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy). * history of regular alcohol consumption. * participation in a clinical trial within 30 days prior to the first dose of study drug.

Keywords: drug-drug interaction
comparison of two types of braces in the treatment of rockwood type iii ac-dislocations

Conditions: Acromioclavicular Joint Dislocation

Summary: in a randomised prospective comparative trial the investigators aim to compare the conservative treatment of acromioclavicular dislocations (rockwood iii) with a conventional sling versus a acromion 2.0 brace, which exerts a direct reposition force on the joint. the sling/brace will be worn for 6 weeks and the patients will be regularly checked clinically and radiologically.the investigators are interested in differences of shoulder function, patient satisfaction as well as cosmetic and radiological results.


Eligibility criteria:
inclusion criteria: * first acute acromioclavicular dislocation rockwood type iii exclusion criteria: * previous injury to acromioclavicular joint * previous surgery of acromioclavicular joint * known hypersensitivity or allergy to fabric of investigational product * pregnancy * known or suspected non-compliance, drug or alcohol abuse * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
evaluation of a respiratory monitor in surgical patients with a bmi>35

Conditions: Obesity; Obstructive Sleep Apnea

Summary: this study proposes to evaluate the clinical applicability of the exspiron respiratory volume monitor (rvm, exspiron™, respiratory motion, inc.; waltham, ma) in obese surgical patients undergoing general anesthesia. previous work has demonstrated the ability of the exspiron monitor to provide non-invasive, real-time, continuous measurements of respiratory parameters such as tidal volume (tv), minute ventilation (mv) and respiratory rate (rr) mostly in normal weight patients but those studies did not specifically look at obese subjects. respiratory depression, in the postoperative setting due to residual anesthetics and/or opioid administration, continues to be a significant cause of adverse outcomes. obese patients are at increased risk for respiratory complications. currently, there is no objective measure of early respiratory indicators for developing respiratory compromise. current respiratory assessment in non-intubated patients relies on oximetry data and subjective clinical assessment. pulse oximetry has been extremely helpful in recognizing oxygen desaturations but it is a late indicator of respiratory decline. there is no current device capable of giving real time ventilatory information such as tidal volume and minute ventilation of a patient that is not mechanically ventilated. the exspiron system utilizes an impedance based technology and proprietary algorithms (respiratory motion inc.) to obtain these measurements. the study hypotheses are that the non-invasive, impedance-based rvm monitor will accurately reflect tv, rr and mv in obese surgical patients before induction of general anesthesia, during controlled ventilation and following extubation; that exspiron will accurately reflect the post-extubation respiratory status of the patient; and that apnea and hypopnea episodes in the recovery room as detected by the exspiron monitor are correlated with the individual risk for obstructive sleep apnea as determined by the stop-bang risk stratification.


Eligibility criteria:
inclusion criteria: * asa 1 - 3 patients with a body mass index (bmi) ≥ 35kg/m2 presenting for elective surgery under general anesthesia aged \> 18 years. ability to provide written informed consent. exclusion criteria: * emergent surgical patients, patients with a bmi \< 35kg/m2, patients not competent to give informed consent, pregnant patients (women of child bearing potential who want to participate will have a pregnancy test done prior to enrollment in the study), patients with implantable electronic devices (pacemakers, stimulators, etc.); predictable interference with surgical procedure or standard of care.

Keywords: respiratory rate tidal volume minute ventilation obese patients obstructive sleep apnea
phase 2b trial comparing hdv-insulin lispro to insulin lispro in adults with type 1 diabetes receiving insulin degludec

Conditions: Diabetes Mellitus, Type 1

Summary: the goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in type 1 diabetes patients. participants will use continuous glucose monitoring to measure the sugar levels in their blood, and work with the doctor to find the best doses. one group of patients will get the liver targeting insulin, and the other group will use insulin they normally use for treating type 1 diabetes. the participant will be part of the study for up to 32 weeks.

individuals age 18 up to 80 years with type 1 diabetes using multiple daily injections of bolus insulin plus basal insulin will be enrolled into a double-blind randomized controlled trial to assess the efficacy, safety, and tolerability of hepatocyte-directed vesicles-insulin lispro (hdv-l) versus lispro alone (lis) used in combination with insulin degludec. the study includes (1), a screening period up to 3 weeks, (2), a run-in period of 2 weeks to assess eligibility and to transition to use of insulin lispro and insulin degludec and unmasked continuous glucose monitoring (cgm), )3), a 12-week dose optimization period to optimize bolus and basal insulin doses,, (4), a 13-week maintenance period, and (5), a 2 -week transition follow-up period. the primary objective of the study is to determine if the addition of hdv to insulin lispro results in an improvement in glycemic control as defined by decreasing evidence of nocturnal hypoglycemia while maintaining or improving glycated hemoglobin (hba1c). other outcomes related to glycemic control will also be evaluated.

Eligibility criteria:
inclusion criteria: * clinical diagnosis type 1 diabetes with c-peptide \<=0.6 ng/ml and using insulin for at least 6 months * willing to use study provided insulin as the only bolus insulin and insulin degludec as the basal insulin * willing to use cgm device throughout the study * screening a1c \>= 6.5% and \<= 10.0% daily insulin dose \<= 1.25 u/kg/day exclusion criteria: * known or specific allergy to any component of the study drug, the active comparator * pregnant or breast-feeding, or plans to become pregnant at any time during duration of study * current use of hydroxyurea * use of noninsulin glucose-lowering medications other than metformin, weight loss medications or dietary supplements for weight loss within 30 days, or anticipated use during the course of the study * received any investigational drug within prior 30 days * clinically significant abnormalities on screening laboratory testing including liver enzymes * presence of a medical condition or use of a medication that could compromise the results of the study or the safety of the subject (eg. alcohol or drug abuse, uncontrolled hypertension, history of transient ischemic attack or stroke within the last 12 months) * employed by or having immediate family members employed by the sponsor or directly involved in conducting the clinical trial.

Keywords: diabetes mellitus type 1 cgm randomized hdv lispro
brugada ablation of vf substrate ongoing multicenter registry

Conditions: Brugada Syndrome

Summary: current treatment of high-risk brugada syndrome (brs) patients (pts) with recurrent vf is limited. catheter ablation (ca) has been performed for brs but a large study with long-term outcomes of ca in brs ablation are lacking.

brugada syndrome (brs) patients who undergo brs substrate ablations from tertiary centers for catheter ablations of complex arrhythmias from three continents - asia, europe and north america - are registered in a common database. the investigators exclude patients who were lost to follow up in the outpatient clinic.

Eligibility criteria:
inclusion criteria: * symptomatic brugada syndrome patients who had undergone catheter ablation of the arrhythmogenic substrates. exclusion criteria: * patients who will not commit to regular follow up.
shanghai eye study for adults

Conditions: Blindness,Visual Impairment, Refractive Error, Cataract, High Myopia, Aging

Summary: blindness and visual impairment severely impact the visual health and life quality of people, particularly the 2.566 million senior citizens aged at 65 and above in shanghai. the main reason is uncorrected refractive error, of which, 62.1% can be solved through refractive correction. for this reason, the uncorrected refractive errors of 154,000 senior citizens in shanghai can be taken as a priority among the public health issues to prevent blindness. now, with the aim to reduce the prevalence rate of blindness and visual impairment, it is planned to establish a public health service mechanism in terms of refractive error screening and correction for the elderly by relying on shanghai's three-level (city-district-community) eye diseases prevention network, using proper refractive correction technology, and moving related services forward to communities in order to screen, identity, and correct blindness and visual impairment caused by refractive errors as early as possible.


Eligibility criteria:
inclusion criteria: * shanghai residents aged ≥18 years old exclusion criteria: * cognitive and/or mobility disorders; non-shanghai residents; younger than 18 years old.
comparison of the effect of total intravenous anesthesia and inhalation anesthesia on cancer cell cytotoxicity, micrometastasis and recurrence of tumor in patients undergoing breast tumor resection

Conditions: Breast Cancer

Summary: the purpose of this study is to compare the effect of total intravenous anesthesia and inhalation anesthesia on cancer cell cytotoxicity, micrometastasis and recurrence of tumor in patients undergoing breast tumor resection. using propofol-remifentanil in total intravenous anesthesia group and sevoflurane -remifentanil in inhalation anesthesia group.


Eligibility criteria:
inclusion criteria: * patient between 20 and 65 of age with asa physical status ⅰ-ⅲ * breast cancer patients with no sign of local invasion (adjacent organs) and distant metastasis revealed by imaging studies * surgery performed by the same surgical team exclusion criteria: * asa physical status ⅳ * hepatic and renal impairment * diabetes or other endocrine disorders * body mass index \> 35 kg/m2 * immune disorders or immunosuppressive therapy * steroid treatment in the last 6 months * inflammation

Keywords: total intravenous anesthesia, inhalation anesthesia, cancer cell cytotoxicity, breast tumor
a study to investigate the safety, tolerability, pharmacokinetic, and efficacy of aby-035/afo2

Conditions: Psoriasis

Summary: the purpose of this first-in-human study of the formulation aby-035/afo2 is to investigate the safety, tolerability and efficacy after multiple doses in sequential escalating dose cohorts in psoriasis subjects.


Eligibility criteria:
inclusion criteria: * diagnosed with plaque psoriasis at least 6 months prior to screening, if suitable for systemic treatment or phototherapy, and if have a stable active plaque-type psoriasis (stable is defined as without clinically significant flares during the 12 weeks before the first dose). subjects with psoriatic arthritis may be included if they have not received systemic treatment within the last 12 months and their disease is stable * subjects must use adequate contraceptive measures from the screening visit until 4 weeks after final administration of the investigational product * subject that has a maximum body weight of 243 pounds (110 kg) exclusion criteria: * subjects with psoriatic arthritis that have received systemic treatment within the last 12 months. * subjects will not be eligible if they have current forms of psoriasis other than chronic plaque-type (e.g. erythrodermic, guttate, or pustular) * subject that has a current drug-induced psoriasis form (e.g. a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium) * subject that has a history of recurrent or medically important infections, a clinically significant candida infection or clinically significant skin infection with staphylococcus aureus requiring systemic treatment in the last 12 months prior to the first administration of study drug * subject that smokes more than 15 cigarettes, or equivalent in tobacco, per day subject with a history of suicide attempt or suicidal behavior * any live vaccination within 3 months prior to screening * subject that is pregnant, intends to become pregnant during the course of the study, or is lactating
urinary tract infections caused by extended-spectrum beta-lactamase-producing enterobacteria

Conditions: Urinary Tract Infections

Summary: urinary tract infections (utis) are one of the most common pathologies encountered in general practice. however, with increasing bacterial resistance to antibiotics, their treatment is becoming increasingly complex. extended-spectrum beta-lactamase-producing enterobacteriaceae (esbl-e) pose a particular challenge due to their increased resistance to many commonly used antibiotics. the aim of this thesis is to study the management of such infections by general practitioners in bas-rhin and to suggest possible avenues for improvement.


Eligibility criteria:
inclusion criteria: * adult (≥18 years old) * subject with an enterobacteriaceae urinary tract infection treated in a primary care setting for urinary tract infection between june 1, 2024 and december 31, 2024 * subject not objecting, after being informed, to the reuse of their data for the purposes of this research. * the subject's primary care physician agreeing to participate in the study exclusion criteria: * subject and/or their primary care physician having expressed their opposition to participating in the study * subject under legal protection * subject under guardianship or curatorship

Keywords: urinary tract infections beta-lactamase enterobacteriaceae
exposure initializes therapy - treatment of homebound patients extended

Conditions: Agoraphobia

Summary: cognitive behavioral treatment of homebound patients with severe agoraphobia.

homebound patients with severe agoraphobia are treated with an exposure focussed cognitive behavioral therapy. the treatment begins at home. with a quick onset of guided exposure, patients get the possibility to develope the capability to reach the regular treatment location on their own very rapidly.

Eligibility criteria:
inclusion criteria: * agoraphobia with/without panic disorder exclusion criteria: * psychotic disorders * bipolar disorders * acute substance dependency
observational post-authorisation safety study of asenapine (sycrest)

Conditions: Manic Disorder

Summary: the purpose of this observational study is to evaluate the use and short term safety of asenapine (sycrest) in real-life usage in the mental health trust setting in the united kingdom(uk) national health service (nhs). the study is to be carried out independently by the drug safety research unit (dsru) in southampton, although it is funded by merck, the manufacturer of sycrest.


Eligibility criteria:
inclusion criteria: * patients for whom a study questionnaire containing useful information has been returned exclusion criteria: * patients who do not provide consent * patients within selected institutions (for example prisons) * patients who commenced treatment between date of market launch (to be confirmed) and study start * enrolled patients for whom both the baseline and 12-week questionnaires are returned blank (contain no clinical information) * enrolled patients for whom the psychiatrist, designated member of clinical care team, or study facilitator from the dsru reports that the patient did not take or was never prescribed asenapine * enrolled patients for whom there is evidence to suggest duplication of patients * enrolled patients for whom informed written or verbal notification is received by dsru indicating that they no longer wish to participate at any stage of the study
a study of shr-a2102 in combination with adebrelimab and shr-8068 in subjects with locally advanced or metastatic non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: this study is a multicenter, open-label, dose-finding/efficacy-expanding phase ib/ii clinical trial to evaluate shr-a2102 in combination with adebelimab in combination with shr-8068 in patients with locally advanced or metastatic non-small cell lung cancer. the study consists of two phases: phase ib to explore the safety/tolerability of shr-a2102 in combination with adebelimab in combination with shr-8068 in patients with locally advanced or metastatic non-small cell lung cancer; phase ii: to explore the efficacy of shr-a2102 in combination with adebelimab in combination with shr-8068 in patients with locally advanced or metastatic non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: 1. subjects are able to give voluntary informed consent, understand the study and are willing to follow and complete all the test procedures. 2. age 18\~70 years old. 3. pathologically confirmed unresectable locally advanced/metastatic non-small cell lung cancer. 4. at least one measurable lesion per recist v1.1 criteria. 5. ecog ps score: 0-1. exclusion criteria: 1. active or symptomatic brain metastases. 2. previous diagnosis of any other malignancy. 3. clinically symptomatic moderate to severe ascites; uncontrollable or moderate or above pleural effusion, pericardial effusion. 4. received anti-tumor therapy 4 weeks prior to initiation of study treatment. 5. uncontrolled tumor-related pain. 6. subjects with severe cardiovascular and cerebrovascular diseases.